Cell ther­a­py biotech from Stan­ford CAR-T leader Crys­tal Mack­all nabs $200M for PhII 

A biotech born out of the work of Stan­ford CAR-T leader Crys­tal Mack­all is pub­licly un­veil­ing its $200 mil­lion Se­ries A Wednes­day, af­ter al­ready go­ing through a Phase I clin­i­cal tri­al, re­brand­ing and set­ting up plans for a po­ten­tial reg­is­tra­tional study.

CAR­GO Ther­a­peu­tics will en­ter a Phase II tri­al lat­er this year with the goal of tak­ing its au­tol­o­gous CD22-tar­get­ed CAR-T cell ther­a­py to the FDA’s doorsteps for an ap­proval in large B-cell lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER